Neuroprotective effect of STAZN, a novel azulenyl nitrone antioxidant, in focal cerebral ischemia in rats

Dose-response and therapeutic window

James J. Ley, Ludmila Belayev, Isabel Saul, David A. Becker, Myron Ginsberg

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Stilbazulenyl nitrone (STAZN) is a potent antioxidant that, in a rat model of transient focal cerebral ischemia, confers significant enduring functional and morphological neuroprotection. This study investigated the influence of dose and time of administration on the neuroprotective effects of STAZN in the intraluminal suture model of middle cerebral artery occlusion (MCAo). Dose response: At 2 and 4 h after the onset of MCAo, animals received intravenously either STAZN (low dose = 0.07 mg/kg, n = 8; medium dose = 0.7 mg/kg, n = 9; high dose = 3.5 mg/kg, n = 9), an equivalent volume of vehicle (30% Solutol HS15 and 70% isotonic saline, 0.37 ml/kg, n = 5) or saline (0.37 ml/kg, n = 5). Only the medium dose improved scores (p < 0.05) on a standardized neurobehavioral test at 1, 2 and 3 days after MCAo. Only the medium dose reduced the total infarction (51%, p = 0.014) compared to controls. These results indicate that STAZN exhibits maximal neuroprotection at the 0.7 mg/kg dose. Therapeutic window: STAZN (0.6 mg/kg) dissolved in dimethylsulfoxide was given intra-peritoneally at 2 and 4 h (n = 11), 3 and 5 h (n = 10), 4 and 6 h (n = 10) or 5 and 7 h (n = 7) after the onset of MCAo. Additional doses were given at 24 and 48 h. Vehicle (dimethylsulfoxide, 2.0 ml/kg, n = 6) was administered at 3, 5, 24 and 48 h. STAZN treatment initiated at 2 or 3 h after the onset of MCAo improved neurological scores (p < 0.001) and reduced total infarction (42.2%, p < 0.05) compared to controls.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalBrain Research
Volume1180
Issue number1
DOIs
StatePublished - Nov 14 2007

Fingerprint

Neuroprotective Agents
Brain Ischemia
Middle Cerebral Artery Infarction
Antioxidants
Dimethyl Sulfoxide
Infarction
Therapeutics
Transient Ischemic Attack
Sutures
stilbazulenyl nitrone
azulenyl nitrone

Keywords

  • Antioxidant
  • Cerebral ischemia
  • Free radical
  • Neuroprotection
  • Reperfusion injury
  • Stroke

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Neuroprotective effect of STAZN, a novel azulenyl nitrone antioxidant, in focal cerebral ischemia in rats : Dose-response and therapeutic window. / Ley, James J.; Belayev, Ludmila; Saul, Isabel; Becker, David A.; Ginsberg, Myron.

In: Brain Research, Vol. 1180, No. 1, 14.11.2007, p. 101-110.

Research output: Contribution to journalArticle

@article{e62928608dd24ffc9b1104aa40749c86,
title = "Neuroprotective effect of STAZN, a novel azulenyl nitrone antioxidant, in focal cerebral ischemia in rats: Dose-response and therapeutic window",
abstract = "Stilbazulenyl nitrone (STAZN) is a potent antioxidant that, in a rat model of transient focal cerebral ischemia, confers significant enduring functional and morphological neuroprotection. This study investigated the influence of dose and time of administration on the neuroprotective effects of STAZN in the intraluminal suture model of middle cerebral artery occlusion (MCAo). Dose response: At 2 and 4 h after the onset of MCAo, animals received intravenously either STAZN (low dose = 0.07 mg/kg, n = 8; medium dose = 0.7 mg/kg, n = 9; high dose = 3.5 mg/kg, n = 9), an equivalent volume of vehicle (30{\%} Solutol HS15 and 70{\%} isotonic saline, 0.37 ml/kg, n = 5) or saline (0.37 ml/kg, n = 5). Only the medium dose improved scores (p < 0.05) on a standardized neurobehavioral test at 1, 2 and 3 days after MCAo. Only the medium dose reduced the total infarction (51{\%}, p = 0.014) compared to controls. These results indicate that STAZN exhibits maximal neuroprotection at the 0.7 mg/kg dose. Therapeutic window: STAZN (0.6 mg/kg) dissolved in dimethylsulfoxide was given intra-peritoneally at 2 and 4 h (n = 11), 3 and 5 h (n = 10), 4 and 6 h (n = 10) or 5 and 7 h (n = 7) after the onset of MCAo. Additional doses were given at 24 and 48 h. Vehicle (dimethylsulfoxide, 2.0 ml/kg, n = 6) was administered at 3, 5, 24 and 48 h. STAZN treatment initiated at 2 or 3 h after the onset of MCAo improved neurological scores (p < 0.001) and reduced total infarction (42.2{\%}, p < 0.05) compared to controls.",
keywords = "Antioxidant, Cerebral ischemia, Free radical, Neuroprotection, Reperfusion injury, Stroke",
author = "Ley, {James J.} and Ludmila Belayev and Isabel Saul and Becker, {David A.} and Myron Ginsberg",
year = "2007",
month = "11",
day = "14",
doi = "10.1016/j.brainres.2007.05.028",
language = "English",
volume = "1180",
pages = "101--110",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Neuroprotective effect of STAZN, a novel azulenyl nitrone antioxidant, in focal cerebral ischemia in rats

T2 - Dose-response and therapeutic window

AU - Ley, James J.

AU - Belayev, Ludmila

AU - Saul, Isabel

AU - Becker, David A.

AU - Ginsberg, Myron

PY - 2007/11/14

Y1 - 2007/11/14

N2 - Stilbazulenyl nitrone (STAZN) is a potent antioxidant that, in a rat model of transient focal cerebral ischemia, confers significant enduring functional and morphological neuroprotection. This study investigated the influence of dose and time of administration on the neuroprotective effects of STAZN in the intraluminal suture model of middle cerebral artery occlusion (MCAo). Dose response: At 2 and 4 h after the onset of MCAo, animals received intravenously either STAZN (low dose = 0.07 mg/kg, n = 8; medium dose = 0.7 mg/kg, n = 9; high dose = 3.5 mg/kg, n = 9), an equivalent volume of vehicle (30% Solutol HS15 and 70% isotonic saline, 0.37 ml/kg, n = 5) or saline (0.37 ml/kg, n = 5). Only the medium dose improved scores (p < 0.05) on a standardized neurobehavioral test at 1, 2 and 3 days after MCAo. Only the medium dose reduced the total infarction (51%, p = 0.014) compared to controls. These results indicate that STAZN exhibits maximal neuroprotection at the 0.7 mg/kg dose. Therapeutic window: STAZN (0.6 mg/kg) dissolved in dimethylsulfoxide was given intra-peritoneally at 2 and 4 h (n = 11), 3 and 5 h (n = 10), 4 and 6 h (n = 10) or 5 and 7 h (n = 7) after the onset of MCAo. Additional doses were given at 24 and 48 h. Vehicle (dimethylsulfoxide, 2.0 ml/kg, n = 6) was administered at 3, 5, 24 and 48 h. STAZN treatment initiated at 2 or 3 h after the onset of MCAo improved neurological scores (p < 0.001) and reduced total infarction (42.2%, p < 0.05) compared to controls.

AB - Stilbazulenyl nitrone (STAZN) is a potent antioxidant that, in a rat model of transient focal cerebral ischemia, confers significant enduring functional and morphological neuroprotection. This study investigated the influence of dose and time of administration on the neuroprotective effects of STAZN in the intraluminal suture model of middle cerebral artery occlusion (MCAo). Dose response: At 2 and 4 h after the onset of MCAo, animals received intravenously either STAZN (low dose = 0.07 mg/kg, n = 8; medium dose = 0.7 mg/kg, n = 9; high dose = 3.5 mg/kg, n = 9), an equivalent volume of vehicle (30% Solutol HS15 and 70% isotonic saline, 0.37 ml/kg, n = 5) or saline (0.37 ml/kg, n = 5). Only the medium dose improved scores (p < 0.05) on a standardized neurobehavioral test at 1, 2 and 3 days after MCAo. Only the medium dose reduced the total infarction (51%, p = 0.014) compared to controls. These results indicate that STAZN exhibits maximal neuroprotection at the 0.7 mg/kg dose. Therapeutic window: STAZN (0.6 mg/kg) dissolved in dimethylsulfoxide was given intra-peritoneally at 2 and 4 h (n = 11), 3 and 5 h (n = 10), 4 and 6 h (n = 10) or 5 and 7 h (n = 7) after the onset of MCAo. Additional doses were given at 24 and 48 h. Vehicle (dimethylsulfoxide, 2.0 ml/kg, n = 6) was administered at 3, 5, 24 and 48 h. STAZN treatment initiated at 2 or 3 h after the onset of MCAo improved neurological scores (p < 0.001) and reduced total infarction (42.2%, p < 0.05) compared to controls.

KW - Antioxidant

KW - Cerebral ischemia

KW - Free radical

KW - Neuroprotection

KW - Reperfusion injury

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=35548984753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548984753&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2007.05.028

DO - 10.1016/j.brainres.2007.05.028

M3 - Article

VL - 1180

SP - 101

EP - 110

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -